Effects of Szeto-Schiller-31 on atherosclerotic development in ApoE knockout mice

Meng Zhang,Jin Cai,Tong Qiao
DOI: https://doi.org/10.3760.cma.j.issn.2096-1863.2017.04.005
2017-01-01
Abstract:Objective To investigate whether Szeto-Schiller-31(SS-31) could suppress the development of atherosclerosis in vivo. Methods Thirty male ApoE (-/-) mice (8 weeks old) fed with western diet were treated with normal saline or SS-31 (1 mg·kg-1·d-1) (15 mice for each group) through subcutaneous injection for 12 weeks. Oil Red O staining was performed to evaluate area and sizes of the plaques. DHE staining and immunohistochemical staining of 8-hydroxy-deoxyguanosine (8-OHdG) was performed to assess the oxidative stress. The aorta ATP contents were assessed by the ATP bioluminescence assay kit. Immunohistochemical staining of CD68 and α-SMA and Masson's trichrome staining were performed to evaluate the composition of atherosclerotic plaque. Biochemical assays were performed to determine the protein level and activity of superoxide dismutase (SOD). The levels of CD36, lipoxygenase-1 (LOX-1) and ATP-binding cassette transporter A1 were immunohistochemically determined to evaluate the cholesterol transport in aorta. Inflammatory factors, including intracellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6) and C-reactive protein (CRP) in serum, were detected through ELISA. Results SS-31 administration reduced the area and sizes of western diet-induced atherosclerotic plaques and changed the composition of the plaques in ApoE (-/-) mice. Oxidative stress was suppressed, as evidenced by the reduced DHE stain, down -regulated 8 -OHdG expression, and increased SOD activity after chronic SS -31 administration. Moreover, systemic inflammation was ameliorated as seen by decreased serum ICAM-1, MCP-1, and IL-6 levels. Most importantly, SS-31 administration inhibited cholesterol influx by down-regulating expression of CD36 and LOX-1 in aorta to prevent lipid accumulation to further suppress the atherosclerotic progression. Conclusion Administration of SS-31 prevents against atherosclerotic formation in ApoE (-/-) mice suggesting that SS31 might be considered to be a potential drug to prevent atherosclerotic progression.
What problem does this paper attempt to address?